Baritor tablet is indicated for the treatment of adult patients with moderate to severely active Rheumatoid Arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.
Baritor tablet is indicated for the treatment of adult patients with moderate to severely active Rheumatoid Arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.
Limitation of Use: Use of Baritor in combination with other JAK inhibitors, biologic DMARDs or with potent immunosuppressants such as Azathioprine and cyclosporine is not recommended.
Baricitinib is a selective and reversible inhibitor of Janus kinase JAK1 and JAK2. Janus kinases (JAKs) are enzymes that transduce intracellular signals from cell surface receptors for a number of cytokines and growth factors involved in haematopoiesis, inflammation and immune function.
Strong OAT3 Inhibitors: Baritor exposure is increased when it is co-administered with strong OAT3 inhibitors (such as probenecid).
Other JAK Inhibitors or Biologic DMARDs: Baritor has not been studied in combination with other JAK inhibitors or with biologic DMARDS.
The most commonly reported adverse drug reactions (ADRs) occurring in 2% of patients treated with Baritor monotherapy or in combination with conventional synthetic DMARDs were increased LDL cholesterol (33.6%), upper respiratory tract infections (14.7%) and nausea (2.8%).
Baricitinib is contraindicated during pregnancy. No information is available on the presence of Baricitinib in human milk.
In case of an overdose, it is recommended that the patient should be monitored for signs and symptoms of adverse reactions. Patients who develop adverse reactions should receive appropriate treatment.
Immunosuppressant
Store at or below 30°C temperature. Keep away from light and wet place. Keep out of reach of children.
